Jimmy J. Hwang
Experienced in Head and Neck Squamous Cell Carcinoma (HNSCC)

Dr. Jimmy J. Hwang

Oncology
1021 Morehead Medical Drive, Building 1, Suite 5300, 
Charlotte, NC 
On Staff At
Accepting New Patients
Offers Telehealth
Experienced in Head and Neck Squamous Cell Carcinoma (HNSCC)
1021 Morehead Medical Drive, Building 1, Suite 5300, 
Charlotte, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jimmy Hwang is an Oncologist in Charlotte, North Carolina. Dr. Hwang is rated as an Experienced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Pancreaticoduodenectomy, and Bone Marrow Aspiration. Dr. Hwang is currently accepting new patients.

His clinical research consists of co-authoring 115 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Head and Neck Squamous Cell Carcinoma (HNSCC).

Graduate Institution
University Of Pittsburgh
Residency
University of Pittsburgh, Internal Medicine
Specialties
Oncology
Licenses
Internal Medicine in NC
Board Certifications
American Board Of Internal Medicine, Medical Oncology
Fellowships
University of Pittsburgh, Hematology and Medical Oncology
Hospital Affiliations
Atrium Health Union
Carolinas Medical Center/behav Health
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Atrium Health Levine Cancer Institute (GI/Gastrointestinal Cancer)
1021 Morehead Medical Drive, Building 1, Suite 5300, Charlotte, NC 28204

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884) in Subjects With Advanced or Refractory Cancer and in Subjects Who Have Progressed During Treatment With a PD-1/PD-L1 Inhibitor as Their Most Recent Therapy
A Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884) in Subjects With Advanced or Refractory Cancer and in Subjects Who Have Progressed During Treatment With a PD-1/PD-L1 Inhibitor as Their Most Recent Therapy
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1, Nonrandomized, Open-Label Investigation of Subcutaneous Ramucirumab Administration in Participants With Advanced Solid Tumors
A Phase 1, Nonrandomized, Open-Label Investigation of Subcutaneous Ramucirumab Administration in Participants With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: February 27, 2023
Intervention Type: Drug
Study Phase: Phase 1
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Enrollment Status: Unknown
Publish Date: May 24, 2022
Intervention Type: Drug, Procedure, Radiation
Study Drugs: mFOLFIRINOX, FOLFOX
Study Phase: Phase 2
An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus MEDI4736 in Patients With Locally Advanced and Unresectable or Metastatic Gastrointestinal or Thoracic Malignancies
An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus MEDI4736 in Patients With Locally Advanced and Unresectable or Metastatic Gastrointestinal or Thoracic Malignancies
Enrollment Status: Completed
Publish Date: January 20, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Dose-Escalation Study of LY2606368 in Combination With Ralimetinib in Patients With Advanced or Metastatic Cancer
A Phase 1 Dose-Escalation Study of LY2606368 in Combination With Ralimetinib in Patients With Advanced or Metastatic Cancer
Enrollment Status: Completed
Publish Date: December 14, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 4 Less Clinical Trials

115 Total Publications

Role of CD47 gene expression in colorectal cancer: a comprehensive molecular profiling study.
Role of CD47 gene expression in colorectal cancer: a comprehensive molecular profiling study.
Journal: Journal for immunotherapy of cancer
Published: October 07, 2024
Similar Doctors
Asim Amin
Distinguished in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Asim Amin
Oncology
Distinguished in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Asim Amin
Oncology

Atrium Health Levine Cancer Institute (Medical Oncology & Immunotherapy)

1021 Morehead Medical Drive, Suite 6100, 
Charlotte, NC 
 (0.2 miles away)
980-442-5310
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Asim Amin is an Oncologist in Charlotte, North Carolina. Dr. Amin is rated as an Elite provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Renal Cell Carcinoma (RCC), Melanoma, Chromophobe Renal Cell Carcinoma, and Clear Cell Sarcoma. Dr. Amin is currently accepting new patients.

Jennifer L. Atlas
Advanced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Jennifer L. Atlas
Hematology | Oncology
Advanced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Jennifer L. Atlas
Hematology | Oncology

Atrium Health Levine Cancer Institute

1021 Morehead Medical Drive, 
Charlotte, NC 
 (0.2 miles away)
980-442-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jennifer Atlas is a Hematologist and an Oncologist in Charlotte, North Carolina. Dr. Atlas is rated as an Advanced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). Her top areas of expertise are Melanoma, Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, and Chromophobe Renal Cell Carcinoma. Dr. Atlas is currently accepting new patients.

Daniel R. Carrizosa
Experienced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Daniel R. Carrizosa
Hematology | Oncology
Experienced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Daniel R. Carrizosa
Hematology | Oncology

Atrium Health Levine Cancer Institute (Thoracic-Pulmonary)

1021 Morehead Medical Drive, Building 2, Suite 30500, 
Charlotte, NC 
 (0.2 miles away)
980-442-3300
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Carrizosa is a Hematologist and an Oncologist in Charlotte, North Carolina. Dr. Carrizosa is rated as a Distinguished provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Lung Cancer, Nasopharyngeal Carcinoma, Pleuropulmonary Blastoma, and Non-Small Cell Lung Cancer (NSCLC). Dr. Carrizosa is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hwang's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 23 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile